Amdizalisib
Marginal Zone Lymphoma
Hutchison Medipharma LimitedSmall moleculePhase 2Dormant
CCC
54/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 73/ 100
Competitive context
106 Active assets in the Marginal Zone Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
ETOPOSIDE University of Miami | Phase 2 | BBB |
Orelabrutinib Henan Cancer Hospital | Phase 4 | BBB |
Fludarabine Paolo Caimi, MD | Phase 2 | BBB |
FILGRASTIM Fred Hutchinson Cancer Center | Phase 2 | BBB |
CYCLOSPORIN A Fred Hutchinson Cancer Center | Phase 2 | BBB |
View all 50 →
Same molecule, other indications
Amdizalisib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →